Antiemetics

11,439 views
10,720 views

Published on

This is an overview of drugs used to control nausea and vomiting. This presentation was for 2nd year pharmacy students as part of a pharmacology & toxicology course and accompanies Goodman & Gilman's (12e) chapter 46.

Published in: Health & Medicine
0 Comments
19 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
11,439
On SlideShare
0
From Embeds
0
Number of Embeds
36
Actions
Shares
0
Downloads
527
Comments
0
Likes
19
Embeds 0
No embeds

No notes for slide
  • Source of painting unknown (Wikipedia)
  • Left: 14th century illustration of vomiting from the CasanatenseTacuinumSanitatis,a medieval handbook on health and wellbeing written in Baghdad. 
  • Emesis is the medical name for vomiting, throwing-up, retching, and puking. This can be a life-saving event (think alcohol poisoning). This may or may not be preceded by nausea.
  • A young, medically qualified patient being treated by combination chemotherapy for sarcoma stated that “the severity of vomiting at time made the thought of death seem like a welcome relief”. Lower right shows offspring of mothers that received thalidomide to treat their morning sickness.
  • There are just a few areas that are outside the BBB (pineal, posterior pituitary, and structures adjacent to the 3rd & 4th ventricles). The area postrema is located adjacent to the most caudal end of the 4th ventricle.
  • The ferret vomited 1.5 hours after chemo administration.
  • Two bottle choice involves saccharine solution versus water.
  • 5-HT3 receptor is present in both the CTZ & NTS but it is unclear if these have an effect on vomiting.
  • Vomiting consists of voluntary (cortex) and involuntary (medulla) components. Vestibular system connects of vomiting center via 8th cranial nerve.
  • Pronounced: on dance ah tron; often combined with dexamethasone (the mechanism for corticosteroid increase in effectiveness of 5-HT3 antagonists is unknown, adverse effects are relatively rare
  • Half-life following oral administration. >90% of serotonin in body is found in GI tract so constipation should come as no surprise with 5-HT3 antagonists. Dolasetron may prolong QT interval so avoid with patients born with congenital long QT syndrome or taking medications that prolong QT (e.g. epinephrine, amitryptyline). These 3 1st generation 5-HT3 antagonists produce largely equivalent effects.
  • Palonosetron has exceptional binding to 5-HT3 and a very long-half life. This is useful as some chemos produce both an acute and delayed nausea. Adverse effects include prolongation of the QT interval.
  • The majority of patients were breast cancer (57%) and the most common chemo was cyclophosphamide (63%). No prophylactic corticosteroids were used.
  • These are adverse events that are believed to be unrelated to the chemotherapy.
  • Benzodiazepines can be quite helpful for anticipatory nausea.
  • Pronunciation:met-oh-klO-pruh-mahyd; also used as a gastroprokinetic as this will stimulate stomach emptying; may also cause dystonias
  • Olanzapine is an atypical anti-psychotic that acts to block D2 > 5-HT2A >5-HT3, antihistamine.
  • Pronunciation: (ap-RE-pi-tant). Substance P is a peptide composed of 11 amino acids and is released following pain. Asthenia (as-thee-nee-uh) is weakness. Fosaprepitant is a prodrug.
  • Although studied here individually, when used for CINV,Aprepitant is often combined with 5-HT3 antagonists and corticosteriods. Note that nausea is listed here but all patients are post-operative.
  • Antiemetics

    1. 1. Antinauseants & Antiemetic Agents Brian J. Piper, Ph.D., M.S. October 16, 2012
    2. 2. Learning objectivesPharmacy students should be able to:1. Explain emesis pathway(s)2. Identify drug targets for antiemetic agents3. Describe mechanism of action of antiemetic agents4. Recognize adverse effects of antiemetic agents Ibn Bultan (1531)
    3. 3. Emesis• A protective reflex that serves to rid the stomach and intestine of toxic substances and prevent their further ingestion.• Vomiting is a complex process that consists of: – Pre-ejection phase: gastric relaxation & retroperistalsis – Retching: rhythmic action of respiratory muscles preceding vomiting and consisting of contraction of abdominal and intercostal muscles and diaphragm against a closed glottis – Ejection: intense contraction of the abdominal muscles and relaxation of the upper esophageal sphincter
    4. 4. Importance• Vomiting is an adverse effect of many clinically useful drugs: – cancer chemotherapy & radiation – opioids – general anesthetics• Nausea may be a component of: – migraines – pregnancy
    5. 5. Area Postrema • surrounds 4th ventricle • outside blood brain barrier & monitors bloodMiller & Leslie (1994). Frontiers in Neuroendocrinology, 15(4), 301-320.
    6. 6. Activity of Area Postrema Following ChemotherapyNeuronal activation (c-fos, arrowheads) in the area postrema (AP)following cisplatin administration (10 mg/kg) to an adult ferret. CC:Central Canal (4th ventricle); NTS: nucleus of the solitary tract; DMXdorsal motor nucleus of vagus nerve.Miller & Leslie (1994). Frontiers in Neuroendocrinology, 15(4), 301-320.
    7. 7. Area Postrema & Nausea • Rats (non-retching) got saccharine, injection (saline or lithium chloride), then two-bottle choiceBernstein et al. (1992). Brain Research, 575, 132-137.
    8. 8. Area Postrema & Nausea• Rats (non-retching) got saccharine, injection (saline or lithium chloride), then two-bottle choice• Lesion of the area postrema eliminated this response.Bernstein et al. (1992). Brain Research, 575, 132-137.
    9. 9. Area Postrema (AP) & Nausea * *• Rats (+AP lesioned) got saccharine, injection (saline or lithium chloride)• Behavioral ratings of response to lithium (Lieing on Belly) were made• Pre-inections, a meal was consumed. Stomach contents were examined.• Area Postrema = chemoreceptor trigger zoneBernstein et al. (1992). Brain Research, 575, 132-137.
    10. 10. Anatomy of Emesis• Chemoreceptor trigger zone (CTZ) in the area postrema (AP) at the bottom of the fourth ventricle has high concentration of: • 5-HT3 (?) • D2 • M1 • NK1 • opioid• The CTZ has connections to the Nucleus of the Tractus Solitarius (NTS) & Reticular Formation (aka vomiting center) which contains: • 5-HT3 (?) • M1 • NK1
    11. 11. M1 D2Krakauer et al. (2005). New England Journal of Medicine, 352, 817.
    12. 12. Classification of antiemetics† some peripheral activity at 5-HT3 receptor;‡ some antihistamine and anticholinergic activity
    13. 13. Ondansetron• MOA: 5-HT3 antagonist• Indications: radiation, chemotherapy, postoperapative• Dosing: 1x/day• Adverse Effects: constipation & headache
    14. 14. 5-HT3 Antagonists (-etron) Compared Granisetron Ondansetron DolasetronBrand name Kytril, Sancuso Zofran AnzemetFDA Approval 1988 1991G 1997Indications chemotherapy chemotherapy chemotherapy radiation radiation radiationHalf-life (hours) 9 4 8Routes of oral, iv, transdermal oral, iv oral, ivadministrationAdverse effects constipation & constipation & headache headaches headaches tachy/bradycardiaGgeneric form available
    15. 15. 5-HT3 Antagonists (-etron) Compared Granisetron Ondansetron PalonosetronBrand name Kytril, Sancuso Zofran AloxiFDA Approval 1988 1991G 2003 (delayed nausea)Indications chemotherapy chemotherapy chemotherapy radiation radiation post-operativeHalf-life (hours) 10 4 40Routes of oral, iv, transderm oral, iv oral, ivadministrationAdverse effects constipation & constipation & headache, constipation, headaches headaches QT
    16. 16. 5-HT3 Antagonists Compared: Efficacy • Chemotherapy patients (N = 563) randomized to receive ondansetron versus palonosetron • Treatment failure = emetic response or rescue medication % of PatientsGralla et al. (2003). Annals of Oncology, 14, 1570-1577.
    17. 17. 5-HT3 Antagonists Compared: Safety • Chemotherapy patients (N = 563) randomized to receive ondansetron versus palonosetronGralla et al. (2003). Annals of Oncology, 14, 1570-1577.
    18. 18. Pathway of Emesis 4 3 15 2
    19. 19. Pavlov’s ExperimentsDuring conditioning, the neutral stimulus (tone)and the US (food) are paired, resulting insalivation (UR).After conditioning, the neutral stimulus (nowConditioned Stimulus, CS) elicits salivation (nowConditioned Response, CR) 19
    20. 20. Classical Conditioning & Nausea• Pre-Conditioning – Neutral Stimulus: hospital environment – Unconditioned Stimulus: chemotherapy – Unconditioned Response: nausea & vomiting• Post-Conditioning – Conditioned Stimulus: hospital environment – Conditioned Response: nausea & vomiting
    21. 21. Metoclopramide• MOA: D2 antagonist, 5-HT3 antagonist• Indications: chemotherapy, post-operative• Adverse Effects: restlessness, Parkinsonian symptoms1 min: http://www.youtube.com/watch?v=dum81RdFrhMPronunciation: http://dictionary.reference.com/browse/metoclopramide?s=t
    22. 22. Olanzapine• MOA: D2 antagonist + others• Indications: acute & delayed CINV• Adverse Effects: Stahl (2008). Essential Psychopharmacology, p. 411.
    23. 23. Dronabinol• Synthetic delta-9-tetrahydrocannabinol (Δ9-THC)• Schedule: III• MOA: Cannabinoid receptors?• AE: dysphoria, postural hypotension
    24. 24. Density of Cannabinoid Receptor 1 (Increased Darkness = more receptors labeled with [3H]CP-55,940) Hekenham et al. (1991) J Neurosci, 11, 563-583.
    25. 25. AprepitantMOA: substance P binds to NeurokininA receptors Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met NeurokininA antagonistIndications: CINV, PONVAdverse Effects: asthenia, constipation, hiccups
    26. 26. NeurokininA Antagonist: Efficacy • Abdominal surgery patients (N=750) randomized to receive oral Aprepitant or Ondansetron • Hours until vomiting or rescue medicationGan et al. (2007). Anesthesia & Analgesia, 104(5), 1082-1089.
    27. 27. NeurokininA Antagonist: Safety • Abdominal surgery patients (N=750) randomized to receive oral Aprepitant or OndansetronGan et al. (2007). Anesthesia & Analgesia, 104(5), 1082-1089.
    28. 28. Summary • High Therapeutic Index • Low Therapeutic Index – 5-HT3 antagonists – cannabinoids – NK1 antagonists – dopamine antagonists – corticosteroids (combo) – benzodiazepinesHesketh (2008). New England Journal of Medicine, 358, 2482-2494.
    29. 29. AbbreviationsCB1 Cannabinoid 1CINV Chemotherapy-induced nausea and vomitingCTZ Chemoreceptor trigger zoneDA DopamineNK1 Neurokinin 1PONV Post-operative nausea and vomitingSTN Solitary tract nucleusVC Vomiting center

    ×